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Fidaxomicin (1, lipiarmycin A3, clostomicin B1, tiacumicin B) constitutes a glycosylated 18-membered macrolactone and is a natural product 
isolated from various soil bacteria. Since 2011, fidaxomicin is a marketed antibiotic for the treatment of intestine infections caused by C. difficile 
in the clinic. Its promising in vitro antibacterial properties against resistant S. aureus and M. tuberculosis continue to attract interest. This review 
article describes the early history of the antibiotic fidaxomicin and highlights recent advances in the field, such as the elucidation of its mode of 
action and biosynthesis, as well as known derivatives. Furthermore, different synthetic strategies towards the total synthesis of fidaxomicin are 
summarized. 
Keywords: Antibiotics • Biosynthesis • Fidaxomicin • Natural Product • Total Synthesis  
 
1. Isolation, Structure Elucidation and 
Biological Activity 
Fidaxomicin (1) is a natural product possessing an 18-membered, 
highly unsaturated macrolactone and is assigned as the first member 
of a new class of antibiotics.[1–3] Antibiotic 1 was first isolated in 1972 
from an actinobacterium, Actinoplanes deccanensis, found in a soil 
sample from India.[4–6] The producer strain was isolated on February 
29th, 1972 – in a leap year – and accordingly, the produced compounds 
were named lipiarmycins. Preliminary structural studies on lipiarmycin 
identified the rhamnoside-dichlorohomoorsellinate moiety as well as 
the modified noviose as important structural features (Figure 1).[7] 
However, lipiarmycin was later reported to actually compose of two 
compounds, lipiarmycin A3 (1) and A4 (9), whose structures were 
finally elucidated after extensive NMR and degradation studies.[8] 
Lipiarmycin A3 consists of an 18-membered macrolactone, which is 
larger than in common macrolide antibiotics (12- to 16-membered 
rings).[9,10]  
The aglycon is at the C(11)-position connected to a modified 
D-noviose, which possesses an isobutyl ester instead of a methoxy 
group at C(4’’)-position.In the C(20)-position the rhamnoside-
dichlorohomoorsellinate moiety is attached.  
 
In contrast, lipiarmycin A4 (9) was found to have a methyl group at the 
homoorsellinic acid in place of an ethyl group. However, the absolute 
configuration on the macrolactone was not yet assigned. Furthermore, 
lipiarmycins B3 (2) and B4 (8) were found and distinguished 
themselves from A3 (1) and A4 (9) by the position of the isobutyric 
ester.[11] While the isobutyric ester in 1 and 9 is attached at the 
C(4’’)-hydroxy group, compounds 2 and 8 bear the isobutyric ester at 
the C(2’’)-hydroxy group. 
More than one decade after the first isolation, in 1986 a Japanese 
research group reported five related antibiotics from Micromonospora 
echinospora subsp. armenica subsp. nov., clostomicins A, B1, B2, C and 
D. [12,13] Clostomicin B1 was found to be identical with lipiarmycin A3 
(1). Furthermore, natural product 1 was isolated a third time from 
Dactylosporangium aurantiacum subsp. hamdenensis subsp. nov. 
together with five additional analogs (tiacumicin A-F)[14,15] and later 
further new tiacumicin analogs were found that are only present in the 
culture broth in small quantities (compounds 5-7 and 15-17).[16] In 
2008, researchers from Novartis isolated macrolactone 1 again from 
Catellatospora sp. Bp3323-81.[17]  
The configuration of the stereogenic center at C(18) was under 
discussion for a long time. In 2005, scientists from Optimer 
Pharmaceuticals enclosed the crystal structure of tiacumicin B in a 
patent and thereby unambiguously assigned the (R)-configuration for 
tiacumicin B and claimed an (S)-configuration for lipiarmycins, 
however, without supporting evidence.[18] In 2015, Serra and coworkers 
closer investigated lipiarmycin A3 and tiacumicin B by comparison of 
NMR spectra of degradation products and could provide evidence for 
the co-identity of those two natural products.[19] Furthermore, in 2017, 
the co-identity of lipiarmycin A3 and tiacumicin B was unambiguously 
verified by single crystal X-ray analysis and revealed the (R)-
configuration, and therefore structural identity, for both lipiarmycin A3 
and tiacumicin B.[20] 
Fidaxomicin (1) was reported to be active against mainly Gram-
positive bacteria including strains insusceptible to other commercial 
antibiotics. Although an anti-cancer activity was reported, 
investigations in these directions have been rarely reported.[21] 
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Figure 1. Structure of fidaxomicin (1) and naturally occurring analogs 2-17. 
Excellent activities were reported against Clostridium difficile (recently 
reclassified as Clostridioides difficile)[22] and Clostridium perfringens as 
well as resistant strains of Staphylococcus aureus and Mycobacterium 
tuberculosis.[12,17,23,24] Cross-resistance was not observed with a broad 
panel of different antibiotics.[5,25]  
 
Moreover, a strong pH dependence of the antibacterial properties was 
discovered. While compound 1 features good antibiotic activities at 
pH = 6, the minimum inhibitory concentration (MIC) increases around 
100 times at pH = 8.6.[5] Incubation of 1 at different pH values and MIC 
determination at a fixed pH value did not result in any effect on the 
activity. The reversibility of the activity implies that pH dependence is 
due to the variation of permeation properties rather than degradation. 
However, a later report from Abbott Laboratories did not confirm this 






Lipiarmycin B (isobutyric ester in C(2’’)-position) is reported to be less 
active than antibiotic 1.[11] Furthermore, all other isolated tiacumicin 
analogs were shown to be less active than the parent compound 1 
against a panel of more than 20 different strains, including 
Staphylococcus aureus, Staphylococcus epidermis, Micrococcus luteus, 
Enterococcus faecium and others.[14] However, the antibacterial activity 
of tiacumicin F (3, isobutyric ester at C(3’’)-hydroxy group) is similar to 
1. 
2. Clinical Application and Future Prospects  
Although possessing activity against a variety of different bacterial 
strains, including some highly pathogenic bacteria that already 
developed resistance against some commercially available antibiotics, 
the clinical use of fidaxomicin (1) is limited to the treatment of 
C. difficile infections (CDI). In 2011, antibiotic 1 was approved for the 
treatment of CDI and it was marketed as Dificlir®. Treatments of 
infections outside the intestinal tract are not yet achieved, due to the 
low water solubility and thus low systemic absorption.[26,27] 
The incidences of CDI are steadily increasing. In the latest report of the 
Centers for Disease Control and Prevention (CDC) in the U.S., an 
alarming trend was mentioned. In 2017, 223’900 people in the U.S. 
were infected with C. difficile, whereof 12’800 died. Therefore, 
C. difficile has been classified as a “urgent threat”.[28] 
CDI often occurs after treatment with antibiotics due to a damaged 
gut flora.[29] In this context, narrow spectrum antibiotics are of great 
interest, as they can combat pathogenic bacteria but are not harmful 
towards others. In this perspective, the narrow spectrum of 
antibacterial activity of 1 is advantageous. Indeed, it belongs to the 
most efficient antibiotics for the treatment of C. difficile infections to 
date. It is reported to show an improved clinical profile compared to 
vancomycin and metronidazole based on better cure and recurrence 
rates. Moreover, antibiotic 1 exhibits a 10- to 100-fold lower MIC 
values for C. difficile compared to other intestinal bacteria and 
therefore a harmful influence on the gut flora is reduced.[30] However, 
besides the hospital acquired CDI, more and more cases of 
community-acquired (individuals considered low risk to get infected) 
CDIs have been reported, which is associated with spread of more 
virulent strains. 
A commonly used method to characterize different C. difficile strains 
is PCR ribotyping which is based on genetic similarity of different 
strains. Notably, in recent years the ribotypes (RT) evolved are 
hypervirulent, such as RT 027, which is in addition highly resistant to 
fluoroquinolones and other antibiotics.[31] No reports have been found 
on fidaxomicin resistant C. difficile, however, this might only be a 
matter of time.[32] Occurrence of the different RTs widely differs 
between geographical regions and changes over time.[33] 
Besides its excellent antibacterial activity against C. difficile, 
macrolactone 1 also shows strong activity against resistant strains of 
S. aureus and M. tuberculosis, the pathogen causing tuberculosis (TB). 
Worldwide, TB is among the top ten causes of death and the World 
Health Organization (WHO) estimated that around 10 million people 
got infected in 2018 and around 1.5 million people died of it.[34] Even 
though, TB is treatable, the treatment can be considered tedious. A 
common therapy for the treatment of drug-susceptible TB disease 
envisages a long-term application (six months) of at least four different 
antibiotics to minimize development of resistances. Unfortunately, 
resistances are developed quite fast and spread globally.  
Although not possessing ideal bioavailability, fidaxomicin’s potential 
of becoming the next generation antibiotic for the treatment of a 
broad spectrum of infections is not yet exploited. In this perspective, 
fidaxomicin could be a promising starting point for the development 




Final author version of the accepted manuscript, (postprint) 
3 
3. Derivatives by Fermentation Studies and 
Semisynthesis 
Although being an interesting target for further modification, only few 
examples on semisynthetic modifications of fidaxomicin (1) are 
documented. In 1995, Abbott Laboratories filed a patent in which they 
reported on the synthesis of dimethylfidaxomicin 18 (Figure 2).[35] 
Methylation of the phenolic hydroxy groups was achieved using 
diazomethane. Although significantly losing activity against most 
investigated bacterial strains, an improved activity against M. luteus 
was reported. Furthermore, benzyl derivative 19 has been reported to 
show diminished RNAP-inhibitory activity.[36]  
Besides these two particular examples, the first and only study on 
semisynthetic derivatives that yielded a greater variety of analogs was 
performed by researchers from Echem Hightech Co.[21] They 
synthesized diversely substituted benzylidene acetals on the diol of the 
noviose moiety (compounds 20-27) and reported on their promising 
anti-cancer activities. However, no antibacterial activities have been 
mentioned.  
 
Figure 2. Structures of known semisynthetic derivatives of 1. 
Moreover, further novel fidaxomicin analogs were produced by 
fermentation (Figure 3). Feeding experiments revealed that chloride 
sources were essential for the successful production of 1. By replacing 
all chloride sources by bromide, four new brominated fidaxomicin 
compounds have been isolated.[37,38] Based on antibacterial 
susceptibility tests, compounds 28 and 30 are more active against 
C. difficile and C. perfringens, while less active against S. aureus, 
S. epidermis and E. faecium. 
 
Figure 3. Known derivatives of 1 obtained by feeding experiments. 
4. Investigation of the Biosynthetic Pathway 
Four decades after the discovery of fidaxomicin (1), the group of Zhang 
and coworkers first reported on the biosynthetic pathway by the 
characterization of the biosynthetic gene cluster of D. aurantiacum 
subsp. hamdenensis, one of the known producer strains.[39] According 
to sequence analysis and analysis of truncated products isolated from 
the fermentation broth of gene-knockout mutants a possible 
biosynthetic pathway was proposed.[40–42] 
They found four genes (tiaA1-A4) encoding for a modular type I 
polyketide synthase (PKS) that is responsible for the synthesis of the 
aglycon 32 (Figure 4). The PKS consist of a loading module and eight 
extending modules. The first step of the biosynthesis is the loading of 
the acyl carrier protein (ACP) with the starter unit, which is proposed 
to be propionyl-CoA. This propionyl starter is then translocated onto 
a ketosynthase (KS) domain of module 1. Next, the extender unit 
malonyl-CoA (33) is loaded onto the ACP of module 1 catalyzed by an 
acyltransferase (AT) and the decarboxylative Claisen condensation 
between propionyl and malonyl units takes place to furnish the 
diketide moiety, which is subsequently reduced by a ketoreductase 
(KR). In this fashion, the whole linear chain is synthesized and modified 
by KR or dehydratase (DH), which installs the alkene moieties upon 
elimination of water. Finally, the linear chain is cyclized and released 
by a thioesterase (TE) to give the macrolactone 32. 
 
Figure 4. Proposed biosynthetic pathway towards fidaxomicin aglycon scaffold 
32 by a multifunctional type I modular polyketide synthase (PKS). tiaA1-A4: 
genes encoding for modular polyketide synthases; AT: acyltransferase specific 
for malonyl-CoA (red), methylmalonyl-CoA (green), ethylmalonyl-CoA (blue); 
ACP: acyl carrier protein; KS: ketosynthase; KR: ketoreductase; DH: dehydratase; 
TE: thioesterase.[39] 
The biosynthesis of the carbohydrate units is not yet fully understood. 
It is known that the noviose moiety 39 and rhamnose moiety 40 
emerge from GDP-D-mannose (36) catalyzed by GDP-mannose-4,6-
dehydratase (Gmd) and GDP-4-keto-6-deoxymannose reductase 
(Rmd) (Scheme 1).[43] In fact, three genes were found in the tiacumicin 
gene cluster that presumably encode for Gmds, namely tiaS1, tiaS3, 
tiaS4. However, no genes were found that are supposed to encode for 
Rmd, which catalyzes the reduction of ketone 37 to rhamnose 38. 
Therefore, it was assumed, one of these enzymes (TiaS1, TiaS3 or 
TiaS4) could act as an Rmd as well. This assumption is supported by 
the existence of bifunctional Gmds that are able to catalyze such 
reductions.  
From GDP-D-rhamnose (38) as a common intermediate, both 
carbohydrate moieties 39 and 40 are biosynthesized through 
methylations induced by C-methyltransferase TiaS2 and 
O-methyltransferase TiaS5, respectively. To confirm the role of TiaS2 
in the biosynthesis, corresponding gene-knockout mutants were 
Final author version of the accepted manuscript, (postprint) 
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prepared and an analog with a lacking methyl group on the 
C(5’’)-position of the noviose (compound 84) was identified, besides 
some products lacking the noviose completely, for example 32 and 49 
(for structures see below, Figure 5). A tiaS5-knockout mutant produced 
analogs, all lacking the C(7’)-methoxy group (major compounds 74 
and 78).  
 
 
Scheme 1. Proposed pathway for the biosynthesis of the modified noviose 39 
and rhamnose 40. TiaS1, S3, S4: GDP-mannose-4,6-dehydratase, TiaS2: 
C-methyltransferase, TiaS5: O-methyltransferase. 
The biosynthesis of the aromatic homoorsellinic acid moiety 47 is 
again derived from a type I PKS. Similar to already known orsellinic 
acid synthases, tiaB is proposed to use a propionyl-CoA (45) instead 
of an acetyl-CoA starter unit, resulting in the installation of an ethyl 
group in resorcinol 47 (Scheme 2). Therefore, using propionyl-CoA as 
starter unit and three malonyl-CoA as extender units the linear 
intermediate 46 is generated, which upon decarboxylative Claisen -
condensation, dehydration and aromatization furnishes the 
homoorsellinic acid 47.  
For further elucidation of the final assembly of natural product 1, 
Zhang and coworkers prepared and cultivated gene-knockout 
mutants of D. aurantiacum and analyzed the produced shunt product 
in order to get detailed information about this process.  
Thereby, TiaP1 and TiaP2 were identified as cytochrome P450s and 
TiaG1 and TiaG2 as glycosyltransferases. 
To probe the functions of these enzymes, the corresponding genes 
were inactivated. The tiaG1-mutants were found to produce 
compounds 32, 41, 48, 49 and 50 lacking the noviose moiety and 
thereby confirming its role as glycosyltransferase for the noviose. In 
contrast, tiaG2-mutants produced compounds lacking the rhamnose 
resorcylate moiety (42, 51-53) and thereby establishing the function 
as glycosyltransferases specific for rhamnosylations. Moreover, tiaP1-
mutant failed to produce 1, solely compound 17 with the missing 
C(18)-hydroxy group was isolated and tiaP2-mutant produced 
compounds lacking the C(20)-hydroxy group (compounds 10, 11, 54-
56).  
The complete catalytic order of the assembly of the final natural 
product 1 remains elusive. However, latest investigations[42] indicated 
that TiaP2 first oxidizes macrocycle 32 at the C(20)-position, before 
glycosyltransferase TiaG1 attaches the noviose to form alcohol 42. 
Then, the isobutyric ester is attached by acyltransferase TiaS6 or 
rhamnosylation occurs to construct fidaxomicin scaffold 43. The 
homoorsellinic acid fragment 47 is then attached. In successive steps, 
the C(7’)-methyl group and the halogenation occur. The last step is 
proposed to be the oxidation of C(18)-position to furnish antibiotic 1. 
All fidaxomicin analogs obtained by Zhang and coworkers are 
summarized in Figure 5 along with their reported antibacterial 
activities against S. aureus. For a more detailed summary, the 
interested reader is referred to reference 44.[44] 
Although, antibacterial activity has not been reported for all 
compounds, a general trend is visible. Accordingly, the noviose and 
rhamnose sugar moiety are crucial for the antibacterial activity of 1 
and analogs missing both or one of these moieties completely lose 
their antibacterial properties with the exception of denoviosylated 49 
and 50, which maintain some antibacterial activity even though 
significantly decreased compared to the parent compound 1. 
Notably, a propyl (analog 70) instead of an ethyl (analog 68) or methyl 
group (analog 69) on the homoorsellinic acid with lacking chloride 
substituents increase the antibacterial activity. 
Ambiguous results are observed for compounds lacking the 
C(18)-hydroxy group. Interestingly, compounds lacking the 
C(18)-hydroxy group and C(7’)-methyl group with different ester 
moieties attached to the noviose (78, 88, 92) retain/improve their 
activities, while compound 76 with the C(18)-hydroxy group attached 
and missing C(7’)-methyl displays decreased activity.  
Oxidation in the C(18)-position to ketone 81 is not tolerated and the 
activity is diminished, whereas methylation in this position, as in 
compound 82, displays improved activity compared to 1. All in all, 
structure-activity relationships are indistinct and do not seem to be 
additive. Moreover, direct comparison of the compounds is usually 
difficult due to simultaneous changes at several positions. 
Modification on one position does not necessarily lead to a loss in 





Scheme 2. Proposed biosynthetic pathway to homoorsellinic acid 47 and assembly of natural product 1. TiaB: iterative type I polyketide synthase (PKS); TiaF: Ketoacyl-

































Figure 5. Reported fidaxomicin analogs obtained by fermentation of gene-knockout mutants and their reported antibacterial activities against S. aureus.
5. Mechanism of Action  
The first report on the mechanism of action of fidaxomicin (1) 
appeared soon after the disclosure of the first isolation. Therein, 
Parenti and coworkers reported that antibiotic 1 interferes with the 
RNA synthesis by inhibiting RNA polymerase (RNAP).[45] The bacterial 
RNAP core enzyme consists of five subunits (ααββ’ω) and an initiation 
factor σ (Figure 6). Upon binding of the σ factor, the so-called 
holoenzyme is formed. Prokaryotic RNAP widely differs from 
eukaryotic RNAP and therefore renders this enzyme a convenient 
target for antibiotics as they specifically act on bacterial RNAP. During 
initiation of the transcription, the σ-factor needs to bind to the core 
enzyme in order to enable binding of the DNA-strand.[46–48] The 
promoter specific σ-factor consist of separate domains 1-4. The 
domains 2 and 4 recognize the −35 and −10 promoter sequences of 
the DNA, respectively, and forms a closed promoter complex (RPC). 
Next, the double-stranded DNA is melted to form an open promoter 
complex (RPO) onto which nucleotides can adhere to build up a new 
RNA strand. 
 
Early on in the investigations on the mechanism of action, Parenti and 
coworkers found when fidaxomicin was added before initiation, the 
RNA synthesis was immediately discontinued, while addition of 
fidaxomicin at an advanced state, when nucleotide polymerization has 
already started, resulted in proceeding of RNA production for several 
minutes before it was suppressed.[45] This finding indicated that 
fidaxomicin interferes with the initiation step rather than elongation. 
Similar results were independently obtained by Clerici and 
coworkers.[49] 
In subsequent years further progress was made towards the 
elucidation of the actual binding site. Studies on B. subtilis mutants 
revealed that fidaxomicin most likely binds to the β-subunit, but also 
the σ-factor was essential for inhibition by interacting with the 
holoenzyme and it was assumed that the formation of the first 
phosphodiester bond is blocked.[50,51] Furthermore, it was reported that 
besides the β-subunit also mutation in β’-subunit lead to resistance 




















57 Z H OH CH3 H 
43 Z H H CH3 H 
58 Z H H H H 
59 H Z H CH3 H 
60 H Z H H H 
61 Y H H CH3 H 
62 Y H H H H 
63 H Y H CH3 H 
64 H Y H H H 
65 H H H CH3 H 
66 H H H H H 








42 H H OH 
51 X H OH 
52 Y H OH 
53 Z H OH 
54 H H H 
10 X H H 
11 Y H H 
55 Z H H 
















1 Z CH3 OH CH3 H CH3 Cl 
68 Z CH3 OH CH3 H CH3 H 
69 Z CH3 OH CH3 H H H 
70 Z CH3 OH CH3 H C2H5 H 
71 Z CH3 OH CH3 H CH3 Cl/H 
30 Z CH3 OH CH3 H CH3 Br/H 
72 Z CH3 OH CH3 H CH3 Br 
28 Z CH3 OH CH3 H CH3 Cl/Br 
9 Z CH3 OH CH3 H H Cl 
73 Z CH3 OH CH3 OH CH3 H 
74 Z CH3 OH H H CH3 Cl 
75 Z CH3 OH H H CH3 H 
76 Z CH3 OH H H H Cl 
77 Z CH3 OH H OH CH3 Cl 
17 Z CH3 H CH3 H CH3 Cl 
44 Z CH3 H CH3 H CH3 H 
78  Z CH3 H H H CH3 Cl 
79 Z CH3 H H OH CH3 Cl 
80 Z CH3 H H H CH3 H 
14 Z CH3 =O CH3 H CH3 Cl 
81 Z CH3 =O CH3 H CH3 H 
82 Z CH3 CH3 H H CH3 Cl 
83 Z CH3 CH3 CH3 H CH3 Cl 
84 Z H OH CH3 H CH3 Cl 
85 Y CH3 OH CH3 H CH3 H 
86 Y CH3 OH H H CH3 Cl 
87 Y CH3 H CH3 H CH3 Cl 
88 Y CH3 H H H CH3 Cl 
89 X CH3 OH CH3 H CH3 H 
90 X CH3 OH H H CH3 Cl 
91 X CH3 H CH3 H CH3 Cl 
92 X CH3 H H H CH3 Cl 
93 H CH3 OH CH3 H CH3 Cl 
94 H CH3 OH CH3 H CH3 H 
15 H CH3 H CH3 H CH3 Cl 
95 H CH3 H CH3 H CH3 H 
Reported minimum inhibitory concentrations (MIC) against 
S. aureus [µg/mL] 
>128 64 32 16 8 <4 n.d. 
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Figure 6. M. tuberculosis RNAP holo enzyme in molecular surface representation 
(PDB: 6FBV)[36] and transcription initiation pathway. Figure adapted from 
reference.[46] 
Later, it was found that fidaxomicin most probably targets the switch 
region and/or the RNA-exit channel. In RNAP, the β- and β’-subunits 
form a pincer-like structure and the two subunits act as mobile clamps 
that can open or block the access to the active site by conformational 
changes. The switch-region is at the base of the RNA clamp and 
induces these necessary conformational changes. It was therefore 
proposed, that fidaxomicin traps one of the inactive and closed 
intermediates and prevents isomerization of RPC to RPO.[53–56] However, 
the role detailed role of the σ-subunit, which is required for promoter 
recognition and DNA unwinding remained elusive. Brodolin and 
coworkers studied the action of σ-subunit mutants and found that 
fidaxomicin competes with the −10 promoter sequence for the same 
binding site and thereby preventing the formation of the RPO.[57] 
The final breakthrough came with the elucidation of the cryo-electron 
microscopy (cryo-EM) structure of fidaxomicin binding to 
M. tuberculosis RNAP, independently disclosed in 2018 by the research 
groups of Campbell and Ebright, respectively.[36,58] These cryo-EM 
structures confirmed the interactions of 1 with the β, β’ as well as σ-
subunits. Moreover, the cryo-EM structure as well as additional 
fluorescence resonance energy transfer (FRET) measurement indicated 
that fidaxomicin traps an open-clamp conformation through 
interaction with the switch-region and thereby traps a wrong spatial 
orientation of σ2- and σ4-units required for simultaneous recognition 
of −10 and −35 promoter elements. 
To summarize, fidaxomicin constitutes an RNAP inhibitor. It inhibits 
transcription of DNA into RNA by binding to the switch-region and 
thereby trapping an open clamp conformation. This prevents 
simultaneous binding to the −35 and −10 promoter elements and 
promoter melting and thus formation of the transcription bubble (RPO) 
is not possible anymore.  
Besides fidaxomicin another prominent member of RNAP inhibitors, 
rifampicin, made it to the market. However, a different mode of action 
accounts for its antibacterial activity. Instead of interfering with the 
initiation, rifampicin binds to the β-subunit close to the RNA channel 
and thereby sterically prevents elongation of the newly formed RNA 
strand.[59]  
Further mode of actions of antibiotics known to inhibit RNAP (not 
marketed drugs) include disruption of holoenzyme assembly, blocking 
conformational dynamics required for nucleotide addition and 
blocking nucleoside triphosphate (NTP) uptake.[48]  
6. Total Syntheses  
Due to its interesting antibacterial properties and chemical scaffold, 
fidaxomicin (1) attracted the interest of several research groups aiming 
for the total synthesis of this complex natural product. In late 2014, 
besides our group[60], also the research groups of Zhu[61] and 
Altmann[62] independently accomplished a synthesis towards the 
protected aglycon which were published at the same time. While 
Gademann and Altmann aimed for the actual (R)-configuration at 
C(18), Zhu synthesized the (S)-isomer (Figure 7). At that time, the co-
identity of tiacumicin B and lipiarmycin A3 has not yet been 
demonstrated. Later in 2017, the group of Roulland and coworkers in 
France also achieved the synthesis of the protected aglycon.[63–65]  
 
 
Figure 7. Summary of the different synthetic approaches towards the synthesis 
of the fidaxomicin aglycon. 
Although the synthetic strategies resemble each other, the order of 
assembly of the fragments vary between the different approaches. For 
instance, Gademann and Zhu applied a ring closing metathesis (RCM) 
between C(4) and C(5) for the final ring closure, while Altmann chose 
a Suzuki cross coupling between C(13) and C(14) and Roulland 
engaged a Yamaguchi macrolactonization. 
Finally, in 2015 our group accomplished the assembly of natural 
product 1 and published the first total synthesis thereof.[66] A further 
total synthesis of another member of the fidaxomicin family, 
tiacumicin A (10), followed in 2018 by our group.[67] Recently, Roulland 
and coworkers also achieved their total synthesis of 1 using optimized 
glycosyl-donors for the selective b-glycosylation.[68] In the following 
section, the different approaches will be presented and compared. 
Apart from these syntheses, also total syntheses of natural products 
containing a similar macrocyclic scaffold, mangrolide A and D, have 
been recently synthetically prepared.[69–71] 
 
Zhu’s Aglycon Synthesis 
Zhu and coworkers[61] started their synthesis with a Brown allylation of 
acetaldehyde with protected allyl alcohol 96 to afford syn-diol 97 in 
92% ee (Scheme 3). After a protection and deprotection sequence, the 
obtained alkene 98 was submitted to hydroboration/oxidation to 
afford the corresponding alcohol followed by a Swern oxidation to 
give aldehyde 99. Next, the methyl alkene moiety was installed using 
a Horner-Wadsworth-Emmons (HWE) reaction with phosphonate 106 
and subsequent reduction and oxidation sequence furnished an 
unsaturated aldehyde which was again submitted to the same reaction 
sequence to afford the aldehyde 100 with both methyl alkene moieties 
installed. Aldehyde 100 was then successfully engaged in an Evans 
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Scheme 3. Total synthesis of the protected fidaxomicin aglycon 104 by Zhu and 
coworkers. CAN: cerium ammonium nitrate; PMP: p-methoxyphenyl; Ipc: 
i-pinocampheyl; DIBAL: diisobutylaluminium hydride; TCBC: 2,4,6-
trichlorobenzoyl chloride; DMAP: 4-dimethylaminopyridine. 
 
install the neighboring stereocenters at C(10) and C(11). The generated 
hydroxy group was protected as a TES ether and the thioester 101 was 
installed using lithium ethyl thiolate. Subsequent reduction of 
thioester 101 to the corresponding aldehyde with DIBAL also led to 
the chemoselective removal of C(17)-TBS group. Another HWE 
reaction with phosphonate 106 furnished, upon reduction and 
oxidation, the aldehyde 102. Next, a Yamaguchi esterification was 
applied to attach fragment 105. Subsequently, allylation of the 
aldehyde function with (−)-Ipc2B(allyl) then afforded the desired 
diastereomer 103. As a final step, Zhu and coworkers performed a ring 
closing metathesis (RCM) using Grubbs’ second-generation catalyst to 
afford the desired (E)-macrolactone 104 together with the undesired 
(Z)-isomer as a 2:1 mixture in 22 steps and 0.5% overall yield.  
Altmann’s Aglycon Synthesis 
In contrast to the linear synthetic approach of Zhu and coworkers, the 
group of Altmann chose a rather convergent approach.[62] Thereby, 
they first envisioned the synthesis of fragment 111 and 118 which 
were later combined to assemble the desired macrolactone 121 
(Scheme 4).  
Starting from the known allylic alcohol 108, oxidation to the 
corresponding aldehyde and subsequent Evans aldol reaction with the 
boron enolate of 112 furnished the syn-aldol product in high 
diastereoselectivity. Next, the oxazolidone was converted into the 
Weinreb amide 109. TES protection of the secondary hydroxy group 
followed by DIBAL reduction of the Weinreb amide furnished the 
corresponding aldehyde in high yields. A Corey-Peterson olefination 
with imine 113 was applied to install the methyl alkene moiety and 
subsequent hydrolysis of the imine afforded aldehyde 110 in high E/Z 
selectivity. Finally, allylation of aldehyde 110 with Leighton’s silacycle 
114 and subsequent TBS protection of the hydroxy group produced 
the desired fragment 111.  
The synthesis of the second fragment 118 commenced with a 
Sharpless kinetic resolution of racemic allylic alcohol 115 followed by 
epoxide opening with in situ generated propynyl lithium to afford 
alkyne 117. Finally, a copper-catalyzed borylation was applied to give 
the boronate 118.  
The assembly of the macrolactone then started with a cross metathesis 
using the second generation Hoveyda-Grubbs catalyst followed by 
hydrolysis of the methyl ester moiety. Due to unintentional TES 
deprotection the material was resubmitted to TES protection 
conditions to give carboxylic acid 120. Next, a Yamaguchi esterification 
with fragment 118 and the final Suzuki cross coupling delivered the 
protected aglycon 121 in 14 steps (longest linear sequence) and an 
overall yield of 6%. Furthermore, global deprotection of the silyl 
groups to furnish unprotected aglycon and selective partial 
deprotection have been successfully conducted as well.  
 
Gademann’s Aglycon Synthesis 
Similar to Zhu’s approach, Gademann and coworkers envisioned the 
final ring closure via an RCM by assembly of three different fragments 
124, 126 and 131 (Scheme 5).[60] 
The synthesis of fragment 124 was achieved starting from ester 122 
via an aldol reaction with acrolein. Subsequently, the primary hydroxy 
group was selectively protected with TBSCl using a dimethyltin 
dichloride mediated protocol, followed by acetylation of the 
secondary hydroxy. DBU then induced acetate elimination to give 
dienoate 123.   
After the reduction of the ethyl ester 123 and oxidation to the 
aldehyde, a Lindgren-Pinnick oxidation furnished the desired 
carboxylic acid fragment 124.  
 
 
Scheme 4. Total synthesis of the fidaxomicin aglycon 121 by Altmann and coworkers. DIPT:  diisopropyl D-tartrate; Bpin: pinacolatoboron.
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Scheme 5. Total synthesis of the fidaxomicin aglycon 135 and 136 by 
Gademann and coworkers. LDA: lithium diisopropylamide; DBU: 
1,8-diazabicyclo[5.4.0]undec-7-ene; DEAD: diethyl azodicarboxylate; HMDS: 
hexamethyldisilazane; PNB: p-nitrobenzyl. 
 
The second fragment was synthesized in a three-step procedure 
starting from epoxide 125. TBS protection of the hydroxy group was 
followed by epoxide opening with propynyl lithium in presence of 
Lewis acid BF3 · Et2O. Finally, Pd-catalyzed hydrostannylation delivered 
the Stille coupling precursor 126 in moderate yields due to low 
regioselectivities.  
Having fragments 124 and 126 in hands, the final assembly was 
performed. Starting from known building block 127, a silyl enol ether 
formation and subsequent vinylogous Mukaiyama aldol reaction 
(VMAR) with (E)-3-iodo-2-methylacrylaldehyde furnished iodide 128. 
Alcohol 128 was submitted to PNB protection using Mitsunobu 
conditions with inversion of the stereocenter, followed by cleavage of 
the oxazilidinone auxiliary under reductive conditions. Next, MnO2-
mediated oxidation to aldehyde 129, successive Brown allylation and 
TBS protection delivered silyl ether 130. 
Then, a protecting group exchange from PNB to TES ether 131 was 
required to successfully apply this substrate in a Stille cross coupling 
reaction to furnish 132 in good yields. Finally, Yamaguchi esterification 
with fragment 124 followed by RCM with second generation Grubbs 
catalyst delivered the desired protected aglycon 134 in an E/Z ratio of 
2:1. Resubmission of the undesired (Z)-134 to 
the metathesis conditions induced isomerization and enabled 
recycling of the (Z)-isomer to afford more of the desired (E)-134. 
Additionally, TES and primary TBS deprotection delivered 
macrolactones 135 and 136 which could be directly engaged in 
glycosylation attempts towards the total synthesis of 1. 
 
Roulland’s Aglycon Synthesis 
The latest report of the aglycone synthesis was published by Roulland 
and coworkers using the C(4)-C(13) fragment 143 as key intermediate 
(Scheme 6).[63,64] For the synthesis of alkyne 143 a [2,3]-Wittig 
rearrangement was applied as a key step. Therefore, the precursor 140 
was prepared starting from diene 137 using a Sharpless epoxidation, 
followed by protection as methoxybenzyl ether (MPM) 138. Then, 
epoxide opening, Parikh-Doering oxidation and the subsequent Wittig 
olefination delivered alcohol 139. After extensive screening, it was 
found that alkyne 140 smoothly undergoes Wittig rearrangement 
upon treatment with n-BuLi and LiCl in high diastereoselectivity to 
furnish, after TES deprotection, alkyne 143. 
 
Scheme 6. Total synthesis of the fidaxomicin aglycon 152 by Roulland and coworkers. MPM: p-methoxybenzyl; DMP:  Dess-Martin periodinane.
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Next, the synthesis of allene 148 commenced with epoxide opening 
with thiophenolate and successive MPM protection of the generated 
hydroxy group, followed by oxidation of thioether furnished 
compound 145. A Pummerer rearrangement, subsequent hydrolysis 
and consecutive Luche propargylation delivered alkyne 146. A 
homologation of alkyne 146 using formaldehyde and a secondary 
amine in presence of CuI furnished the allene 147 and 148. 
With those two fragments in hands, an alkyne/allene cross coupling 
was applied to connect the building blocks 143 and 148 to afford 
alkyne 149. Installation of the methyl group was achieved via 
hydrosulfuration and application of a Kumada-Corriu coupling. Next, 
cross metathesis with alkene 153 and Suzuki cross coupling with 
bromide 154 delivered the aglycon scaffold 151, which upon 
Yamaguchi macrolactonization gave the protected aglycon 152. 
 
Gademann’s Total Synthesis of Fidaxomicin 
The first reported total synthesis of natural product 1 was achieved in 
the Gademann group in 2015.[66] After the successful synthesis of the 
core macrolactone 135, the focus was set on the synthesis of the 
carbohydrate fragments 161 and 165 (Scheme 7). The 
dichlorohomoorsellinic acid moiety was constructed starting from 
dioxinone 155. Claisen condensation and following 
cyclization/aromatization furnished phenol 156. Next, dichlorination 
was achieved using sulfonyl chloride and subsequent allyl protection 
furnished the target building block 157. 
 
 
Starting from the known rhamnoside 158, acetal protection of the 
trans-diol enabled selective methylation of C(2’)-hydroxy group, 
followed by removal of the acetal under acidic aqueous conditions. 
Then, a thiophenyl group was installed in the anomeric position using 
ZnI and TMSSPh, which was then reacted with fragment 157 to furnish 
protected rhamnosyl-resorcylate 160. The free phenolic hydroxy 
group was then allylated and a leaving group exchange in the 
anomeric position was required for optimal results at a later stage. 
Therefore, hydrolysis of thiophenol using NBS in aqueous acetone, 
followed by installation of trifluoroacetimidate gave glycosyl donor 
161. Next, the synthesis of the noviose moiety was commenced with 
iodopyranoside 162. A Zn-mediated Vasella ring contraction followed 
by treatment with 2,2’-DMP and CSA in MeOH furnished furanose 163. 
Ozonolysis in methanolic NaOH smoothly delivered the corresponding 
ester, followed by Grignard reaction with double addition of CH3MgBr 
to form the gem-dimethyl moiety of 164. Furanose 164 was then 
treated with TFA in MeOH to first achieve acetal deprotection and then 
induced ring expansion to obtain the desired pyranoside. 
Subsequently, the diol was protected with a carbonate group using 
CDI and the remaining hydroxy group was esterified with i-
propylchloroformate. Finally, the anomeric position was brominated 
using HBr in AcOH to furnish the attempted glycosyl donor 165. 
Having aglycon 135 already in hands, several attempts were made to 
perform the noviosylation.  
Unfortunately, these attempts remained unsuccessful due to a low 
reactivity of the aglycon towards a variety of different glycosyl donors 
or exclusively unintended α-selectivity as described in a PhD thesis.[72] 
 
 
Scheme 7. Total synthesis of fidaxomicin (1) by Gademann and coworkers. CSA: camphorsulfonic acid; TFA: trifluoroacetic acid; TBAI: tetrabutylammonium iodide; 
NBS: N-bromosuccinimide; 2,2’-DMP: 2,2’-dimethoxypropane; CDI: carbonyldiimidazole. 
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Scheme 8. Total synthesis of tiacumicin A (10) by Gademann and coworkers.
As a consequence, the synthetic strategy had to be reassessed and 
glycosylation with noviosyl bromide 165 was performed on 
macrocycle fragment 130 using Helferich’s conditions before the 
aglycon was assembled. Next, Yamaguchi esterification of fragment 
167 with carboxylic acid 124 delivered boronate 168. Subsequently, a 
Suzuki cross coupling followed by ring closing metathesis yielded β-
noviosylated aglycon 170. After deprotection of the primary TBS 
group, rhamnosylation with acetimidate glycosyl donor 161 was 
performed and delivered  
fully protected fidaxomicin 171 in good β-selectivity. Finally, global 
deprotection yielded the desired natural product 1 in moderate yields. 
Gademann’s Total Synthesis of Tiacumicin A 
Tiacumicin A is a natural product that has been isolated along with 
antibiotic 1 from the fermentation broth. In comparison to 1, 
tiacumicin A constitutes a mono-glycosylated variant of fidaxomicin 
aglycon, with lacking hydroxy groups in C(18)- and C(20)-position and 
an acetyl- instead of isobutyric ester on the noviose (Scheme 8). Based 
on the successful approach using early glycosylation on known 
fragment 130.1 as the key step, tiacumicin A was prepared.[67] The 
synthesis of the C(14)-C(19) fragment 173 with a lacking hydroxy 
group in C(18)-position started with epoxide opening of commercially 
available epoxide 172 with propynyl lithium in presence of BF3·OEt2 
and subsequent borylation of the generated alkyne to give boronate 
173. For the synthesis of the noviose glycosyl donor 175, the common 
intermediate 164.1 from the total synthesis of 1 was used and the 
acetyl group was installed using acetic anhydride. Furthermore, 
replacement of the leaving group in the anomeric position was 
performed as previously described to furnish bromide 175, which was 
carried on to glycosylation with known fragment 130.1. Finally, the 
Suzuki cross coupling of iodide 176 with boronate 174 afforded 
intermediate 177 which was subsequently submitted to RCM in 
presence of Grubbs second generation catalyst. Upon removal of the 
protecting groups, the natural product 10 was obtained. 
Norsikian and Roulland’s Total Synthesis of Fidaxomicin 
Recently, Roulland and coworkers published the second total synthesis 
of fidaxomicin, addressing the issue of the challenging b-selective 
glycosylations.[68]In contrast to the total synthesis of Gademann and 
coworkers, they performed the rhamnosylation (instead of the 
noviosylation) early on in the synthesis on a macrocycle precursor 
fragment (Scheme 9). The b-selective noviosylation was applied at a 
late stage on the fully installed macrocyclic part using a H-bond-
directed b-glycosylation strategy.  
The synthesis of the rhamnosyl-resorcylate moiety started from 
commercially available orsellinic acid analog 179. Dichlorination with 
sulfuryl chloride, TBS-protection of the phenolic hydroxy group and 
benzylic methylation afforded the desired dichlorohomoorsellinic acid 
scaffold 180. Next, acidic hydrolysis and subsequent acetonide 
protecting followed by re-protection of the free phenol delivered the 
fully protected glycosylation precursor 181. 
The synthesis of the rhamnosyl donor commenced with the 
deprotection of the known acetyl-protected mannopyranoside 182 
using Zemplén’s conditions, followed by benzylidene acetal protection 
of the obtained diol. Subsequently, selective TBS-protection of 
C(3’)-OH, methylation at C(2’)-OH, followed by global deprotection 
delivered triol 184. Next, a tosyl protecting group was selectively 
installed at the primary hydroxy group, followed by reduction to install 
the desired C(6’)-methyl group. Finally, glycosylation with 
homoorsellinate 181, oxidation of the thiophenyl group with m-CPBA 
and installation of napthyl and picolinic acid protecting groups 
furnished the desired rhamnosyl-homoorsellinate glycosyl donor 186.   
Furthermore, the noviosyl donor 192 was prepared starting from 
D-arabinose (187). Acetonide protection of the cis-vicinal diol, 
oxidation to the lactone and subsequent TBS-protection delivered 
lactone 188. Grignard addition to the lactone resulted in the 
installation of gem-dimethyl group. The open diol was then re-
oxidized using TEMPO and TCCA to obtain a lactone which was in turn 
reduced using DIBAL to furnish noviose 189. Then, acetonide 
deprotection and conversion into thiophenyl glycosyl donor with 
subsequent protection of the free hydroxy groups gave 190. In order 
to achieve high selectivity in the novioslyation of the macrocycle 
fragment, installation of suitable protecting groups was required. 
Therefore, several protection- and deprotection steps were carried out 
to obtain after oxidation of the anomeric thiophenyl group, the 
required glycosyl donor 192.  
Having, those fragments in hands, the assembly of the natural product 
1 was attempted. After extensive screening, Roulland and coworkers 
found that glycosylation using rhamnosyl donor 186 and acceptor 192 
via activation by Tf2O in presence of DTBMP and ADMB delivered 194 
in high b-selectivity (a/b = 1:20) due to an H-bond mediated Aglycon 
Delivery (HAD) mediated by the picoloyl protecting group. Next, a 
protecting group exchange from the picoloyl- to a TBS-protecting 
group was carried out. The assembly of the macrocyclic core 197 was 
achieved via a Suzuki cross coupling with known, advanced fragment 
196,[63] selective ester hydrolysis using Me3SnOH and subsequent 
Shiina macrolactonization.  
Next, the second glycosylation was performed with noviosyl donor 
192 via HAD, which delivered the desired fidaxomicin scaffold 198 in 
high stereoselectivity (a/b > 1:20). After global deprotection, the 








Scheme 9. Total synthesis of fidaxomicin (1) by Roulland and coworkers. Nap: napthyl, PTSA: p-toluenesulfonic acid; Ts: tosyl; m-CPBA: m-chloroperoxybenzoic acid; 
DCC: N,N′-dicyclohexylcarbodiimide; TEMPO: 2,2,6,6-tetramethyl-1-piperidinyloxyl; TCCA: trichloroisocyanuric acid; DTBMP: 2,6-di-tertbutyl-4-methylpyridine; ADMB: 
4-allyl-1,2-dimethoxybenzene; DDQ: 2,3-dichloro-5,6-dicyano-1,4-benzoquinone; NDMBA: N,N’-dimethylbarbituric acid. 
 
7. Conclusion 
Among a variety of different naturally occurring fidaxomicin-like 
natural products, fidaxomicin possesses the highest activity against a 
broad panel of different bacterial strains. Although 1 was already 
discovered in the 1970s, it was not until 2011 when it was introduced 
to the market as an antibiotic for the treatment of CDI. Besides its 
antibacterial properties, also anti-cancer activities are reported for 
some fidaxomicin analogs. Regarding the current alarming situation 
concerning antibiotic resistance and the associated urgent need of 
new antibiotics, fidaxomicin analogs might be prospective antibiotic 
drug candidates. Recent insights into the biosynthetic pathway, mode 
of action and the experience gained through synthetic studies opens 
new perspective towards the design and synthesis of improved 
fidaxomicin derivatives. 
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